CDSCO Antibiotic Advisory: What Clinics Must Do Now

On 21 September 2026, India’s drug regulator issued a circular that every clinic owner should read closely. The CDSCO antibiotic advisory asks doctors, pharmacists, hospitals and state regulators to stop the casual use of painkillers and antibiotics. It links that misuse to chronic kidney disease, adverse drug reactions and antimicrobial resistance. For clinics, the message is clear: every prescription for these drugs should be justified, correctly dosed and easy for a pharmacist to trust.

The circular came from the Central Drugs Standard Control Organisation (CDSCO). As Business Today reported on 22 September 2026, it does not create a new ban or a new drug category. Instead, it calls for strict compliance with prescription rules that already exist. Below we explain what the advisory says, why the regulator acted now, and the practical changes a busy OPD can make this week.

What the CDSCO antibiotic advisory actually says

The advisory is based on the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945. It focuses on two groups of prescription-only medicines. Most NSAIDs (non-steroidal anti-inflammatory painkillers) fall under Schedule H, and most antibiotics fall under Schedule H1. According to the SCC Online legal summary published on 25 September 2026, the circular gives separate guidance to each group in the medicine chain:

• Doctors and healthcare professionals: prescribe only when there is a clinical need. Use the lowest effective NSAID dose for the shortest suitable duration, and follow antimicrobial stewardship principles.
• Pharmacists and retailers: follow Schedule H and H1 rules, refuse sales without a valid prescription and do not help patients self-medicate.
• Hospitals and institutions: strengthen stewardship programmes, review prescriptions and counsel patients on using medicines rationally.
• Patients: do not self-medicate, do not take antibiotics for viral infections, and tell your doctor about any kidney risk factors before taking a painkiller.
• State and UT drug control authorities: raise public awareness and push for compliance with prescription-only sale.

The doctor guidance is detailed. According to Organiser’s report of 23 September 2026, prescribers should consider a patient’s age, kidney function and co-morbidities before prescribing. Business Today adds that doctors should also check the patient’s other medicines. The regulator also named several practices to avoid, including unnecessary combination therapy, the wrong choice of antibiotic, incorrect dosing and courses that run longer than needed.

Why regulators are tightening antibiotic prescribing now

Two public-health problems sit behind the circular. The first is kidney harm. NSAIDs are among India’s most commonly used medicines, and taking them repeatedly without supervision can damage the kidneys. The risk is highest in older patients and in people who already have diabetes, hypertension or kidney disease. That is why the advisory focuses on renal risk.

The second is antimicrobial resistance (AMR). The World Health Organization’s Global Antibiotic Resistance Surveillance Report, released on 13 October 2025, found that one in six lab-confirmed bacterial infections worldwide in 2023 were resistant to antibiotic treatment. In the WHO South-East Asia Region, which includes India, the figure was one in three. WHO also found that between 2018 and 2023, resistance rose in more than 40% of the pathogen-antibiotic combinations it tracked, at an average of 5–15% a year.

Every antibiotic course that isn’t needed, such as one prescribed for a simple viral fever or stopped halfway, speeds up that trend. Hospitals get most of the attention, but outpatient clinics write a large share of India’s antibiotic prescriptions. The advisory therefore puts responsibility on the neighbourhood GP as well as the tertiary-care ICU.

What this means for doctors and clinic owners

For a well-run practice, the advisory changes little on paper, because these rules already existed. In practice, though, closer enforcement at the pharmacy counter means weak prescriptions will cause more problems. The patient pays the price when a pharmacist turns away an unclear, unsigned or incomplete prescription. The clinic’s reputation suffers too.

Clinics should now focus on three things:

1. Prescriptions a pharmacist can trust. Pharmacists are being told to refuse sales without a valid prescription, so the prescription needs to be complete, legible and verifiable. Handwritten slips and WhatsApp photos of prescriptions invite doubt at the counter.

2. A documented reason for every antibiotic. The advisory mentions stewardship, prescription review and avoiding antibiotics for viral infections. Clinics need a record of why an antibiotic or NSAID was given, including the history, the findings and the patient’s kidney-risk factors. Good clinical documentation is what makes a later prescription review possible.

3. Safety checks before the prescription goes out. The regulator asks doctors to consider the patient’s other medicines, avoid unnecessary combinations and use correct doses. Those checks should happen before the prescription is signed, not after the patient reaches the pharmacy.

Small clinics can start today with a short internal protocol. Record kidney-risk factors in the notes. Avoid antibiotics for clearly viral presentations. Explain to patients why they are not getting an antibiotic. Once a month, review a sample of your antibiotic prescriptions against these points.

How InstaPraxis supports safer, verifiable prescribing

InstaPraxis is the unified clinic OS from InstaDataHelp, built in India for Indian practices. It does not replace the doctor’s clinical judgement, but it gives that judgement a safer and more transparent workflow. The features most relevant to the CDSCO antibiotic advisory are:

• Drug-interaction Rx-safety gate. Before a prescription is sent, InstaPraxis checks it for drug interactions. According to the product brochure, 100% of prescriptions are checked before send. This helps with the advisory’s point about considering other medicines and avoiding unnecessary combinations.
• QR-verified prescriptions. Every prescription carries a QR code that a pharmacist can scan to check that it is authentic in real time. This matters now that pharmacies are being asked to refuse invalid prescriptions.
• AI clinical scribe with bilingual SOAP notes. The scribe turns a Hindi and English consultation into a structured SOAP note. That gives the clinic a written record of history, findings and the reason for treatment, which a stewardship review needs. The brochure cites 3.2× faster documentation vs paper.
• Audit-logged records. Every action is logged, so a clinic can review its own prescribing patterns in an internal stewardship or quality review.
• Role-aware AI agents. The Doctor Agent can answer questions like “What did I prescribe Mrs Iyer last visit?”, which helps doctors catch repeat courses. Each agent asks for explicit confirmation before changing any data.
• Plain-language lab-report AI. This feature explains lab results to patients in simple language. It can support the patient counselling that the advisory asks hospitals and clinics to provide.

InstaPraxis’s AI outputs are decision-support for the treating clinician, not diagnosis. The doctor always decides whether an antibiotic or NSAID is appropriate. The platform’s job is to make that decision well documented, checked for interactions and verifiable at the pharmacy counter. You can read more about digital prescribing on the InstaDataHelp blog.

A practical compliance checklist for this week

Use this short checklist to bring your clinic in line with the spirit of the advisory:

• Audit your prescription format. Make sure every prescription clearly shows the prescriber’s details, registration number, date, patient details, drug, dose, frequency and duration.
• Make prescriptions verifiable. Move away from handwritten or photographed slips to digital prescriptions that pharmacists can check.
• Record kidney-risk factors. Note age, diabetes, hypertension, existing kidney disease and current medicines before prescribing NSAIDs.
• Default to “no antibiotic” for viral illness. Write down the reasoning when you decide not to prescribe one. That record protects you and educates the patient.
• Run a monthly prescription review. Pick a sample of antibiotic and NSAID prescriptions and check dose, duration and combinations.
• Counsel and follow up. Tell patients why finishing a course, or skipping an unnecessary one, matters, and set up a follow-up reminder.

The advisory reiterates existing law, but stricter enforcement at the pharmacy counter means prescribing gaps will now surface much faster.

Frequently Asked Questions

What is the CDSCO antibiotic advisory of September 2026?

It is a circular that the Central Drugs Standard Control Organisation issued on 21 September 2026. It asks doctors, pharmacists, hospitals and state regulators to stop the indiscriminate use of NSAID painkillers and antibiotics, citing the risks of chronic kidney disease, adverse drug reactions and antimicrobial resistance.

Does the advisory create a new ban on painkillers or antibiotics?

No. Business Today and SCC Online both report that it reiterates the existing prescription-only rules for Schedule H and Schedule H1 medicines under the Drugs Rules, 1945. It does not introduce a new ban or a new drug category.

What should clinics change after the advisory?

Clinics should issue complete, verifiable prescriptions and record why each antibiotic or NSAID was prescribed, including kidney-risk factors. They should check for drug interactions and combinations before prescribing, avoid antibiotics for viral illness and review a sample of prescriptions regularly.

How can clinic software help with antibiotic stewardship?

Software such as InstaPraxis can check every prescription for drug interactions before it is sent and add a QR code that pharmacists can verify. It also produces structured SOAP notes and keeps an audit log. The clinical decision always stays with the doctor.

Sources

• Business Today: government cracks down on painkiller and antibiotic misuse (22 September 2026)
• SCC Online: CDSCO issues stakeholder-specific guidance on NSAIDs and antibiotics (25 September 2026)
• Organiser: CDSCO warns against unregulated painkillers and antibiotics over kidney disease risks (23 September 2026)
• World Health Organization: widespread resistance to common antibiotics worldwide (13 October 2025)

Want every prescription from your clinic to be checked for interactions, well documented and verifiable by the pharmacist? Start a 30-day InstaPraxis pilot with all features unlocked and no lock-in, or write to info@instadatahelp.com to book a demo.